Medical societies representing all three specialties issued a joint statement Jan. 21, criticizing studies claiming such scans pose risk of potential patient harm. 

2026 may be the year that many if not most healthcare leaders arrive at a fork in the road to mature AI implementation. 

The U.S. Department of Justice said the defendants, five ophthalmology clinics in Florida, would pay kickbacks to a testing company that performed unnecessary transcranial Doppler ultrasounds. Prosecutors said an investigation into incidents of Medicare and Medicaid fraud stemming from the conspiracy is ongoing.

CMS is considering substantial updates to its TAVR policies, including coverage for asymptomatic patients. Some stakeholders are excited, embracing the possibility of expanded indications and fewer restrictions. Others are concerned that the changes would be too much, too soon.

Where have the missing rural American hospitals gone? And where is rural healthcare headed? The discussion is on in Washington and elsewhere.  

Just because a healthcare AI product gets loudly promoted doesn’t mean its claims are bogus. The salient question is whether or not it performs as well in a clinical setting as it did in a research lab—or in a marketer’s mind. 

Vapor 2000 and Vapor 3000 devices manufactured by Draegar were improperly cleaned after parts were soldered on, meaning toxic metals could mix with medical gases. Due to the high risk posed to patient health, this recall has earned the FDA’s most serious designation. 

Boston Scientific sent all known customers a letter on December 19, 2025 alerting them to an issue with certain AXIOS Stent and Electrocautery Enhanced Delivery Systems. During deployment, the stents may not expand. This can cause severe, potentially life-threatening injury to patients. All recalled stents must be removed from clinical settings immediately.